338 related articles for article (PubMed ID: 27217465)
1. Biomarker Panel for Chronic Graft-Versus-Host Disease.
Yu J; Storer BE; Kushekhar K; Abu Zaid M; Zhang Q; Gafken PR; Ogata Y; Martin PJ; Flowers ME; Hansen JA; Arora M; Cutler C; Jagasia M; Pidala J; Hamilton BK; Chen GL; Pusic I; Lee SJ; Paczesny S
J Clin Oncol; 2016 Aug; 34(22):2583-90. PubMed ID: 27217465
[TBL] [Abstract][Full Text] [Related]
2. CXCL9 Predicts Severity at the Onset of Chronic Graft-versus-host Disease.
Giesen N; Schwarzbich MA; Dischinger K; Becker N; Hummel M; Benner A; Radujkovic A; Müller-Tidow C; Dreger P; Luft T
Transplantation; 2020 Nov; 104(11):2354-2359. PubMed ID: 31929430
[TBL] [Abstract][Full Text] [Related]
3. Pretransplantation Plasma ST2 Level as a Prognostic Biomarker of 1-Year Nonrelapse Mortality in Allogeneic Hematopoietic Cell Transplantation.
Gjærde LK; Ostrowski SR; Schierbeck F; Andersen NS; Friis LS; Kornblit B; Petersen SL; Schjødt I; Sengeløv H
Transplant Cell Ther; 2023 Feb; 29(2):97.e1-97.e6. PubMed ID: 36375798
[TBL] [Abstract][Full Text] [Related]
4. Regenerating islet-derived protein 3-α is a prognostic biomarker for gastrointestinal chronic graft-versus-host disease.
DePriest BP; Li H; Bidgoli A; Onstad L; Couriel D; Lee SJ; Paczesny S
Blood Adv; 2022 May; 6(10):2981-2986. PubMed ID: 35030629
[TBL] [Abstract][Full Text] [Related]
5. A Multiparameter Prognostic Risk Score of Chronic Graft-versus-Host Disease Based on CXCL10 and Plasmacytoid Dendritic Cell Levels in the Peripheral Blood at 3 Months after Allogeneic Hematopoietic Stem Cell Transplantation.
Chirumbolo G; Dicataldo M; Barone M; Storci G; De Matteis S; Laprovitera N; Sinigaglia B; Barbato F; Maffini E; Cavo M; Bonifazi F; Arpinati M
Transplant Cell Ther; 2023 May; 29(5):302.e1-302.e8. PubMed ID: 36796518
[TBL] [Abstract][Full Text] [Related]
6. Plasma CXCL9 elevations correlate with chronic GVHD diagnosis.
Kitko CL; Levine JE; Storer BE; Chai X; Fox DA; Braun TM; Couriel DR; Martin PJ; Flowers ME; Hansen JA; Chang L; Conlon M; Fiema BJ; Morgan R; Pongtornpipat P; Lamiman K; Ferrara JL; Lee SJ; Paczesny S
Blood; 2014 Jan; 123(5):786-93. PubMed ID: 24363401
[TBL] [Abstract][Full Text] [Related]
7. CD19+CD21low B cells and CD4+CD45RA+CD31+ T cells correlate with first diagnosis of chronic graft-versus-host disease.
Greinix HT; Kuzmina Z; Weigl R; Körmoczi U; Rottal A; Wolff D; Kralj M; Kalhs P; Mitterbauer M; Rabitsch W; Edinger M; Holler E; Pickl WF
Biol Blood Marrow Transplant; 2015 Feb; 21(2):250-8. PubMed ID: 25460358
[TBL] [Abstract][Full Text] [Related]
8. Proteomic Characterization Reveals That MMP-3 Correlates With Bronchiolitis Obliterans Syndrome Following Allogeneic Hematopoietic Cell and Lung Transplantation.
Liu X; Yue Z; Yu J; Daguindau E; Kushekhar K; Zhang Q; Ogata Y; Gafken PR; Inamoto Y; Gracon A; Wilkes DS; Hansen JA; Lee SJ; Chen JY; Paczesny S
Am J Transplant; 2016 Aug; 16(8):2342-51. PubMed ID: 26887344
[TBL] [Abstract][Full Text] [Related]
9. Predictive Value of Clinical Findings and Plasma Biomarkers after Fourteen Days of Prednisone Treatment for Acute Graft-versus-host Disease.
McDonald GB; Tabellini L; Storer BE; Martin PJ; Lawler RL; Rosinski SL; Schoch HG; Hansen JA
Biol Blood Marrow Transplant; 2017 Aug; 23(8):1257-1263. PubMed ID: 28478120
[TBL] [Abstract][Full Text] [Related]
10. Association of Plasma CD163 Concentration with De Novo-Onset Chronic Graft-versus-Host Disease.
Inamoto Y; Martin PJ; Paczesny S; Tabellini L; Momin AA; Mumaw CL; Flowers MED; Lee SJ; Carpenter PA; Storer BE; Hanash S; Hansen JA
Biol Blood Marrow Transplant; 2017 Aug; 23(8):1250-1256. PubMed ID: 28455006
[TBL] [Abstract][Full Text] [Related]
11. Incidence and prognostic value of eosinophilia in chronic graft-versus-host disease after nonmyeloablative hematopoietic cell transplantation.
Ahmad I; Labbé AC; Chagnon M; Busque L; Cohen S; Kiss T; Lachance S; Roy DC; Sauvageau G; Roy J
Biol Blood Marrow Transplant; 2011 Nov; 17(11):1673-8. PubMed ID: 21601640
[TBL] [Abstract][Full Text] [Related]
12. [Clinical study of the cytokine panel in the diagnosis of ocular chronic graft-versus-host disease].
Cheng XJ; Ji R; Huan RH; Huang SQ; Fan W; Zhao YC; Yuan RD; Wang XQ; Zhang X
Zhonghua Xue Ye Xue Za Zhi; 2024 Mar; 45(3):242-248. PubMed ID: 38716595
[No Abstract] [Full Text] [Related]
13. Assessment of ST2 for risk of death following graft-versus-host disease in pediatric and adult age groups.
Rowan CM; Pike F; Cooke KR; Krance R; Carpenter PA; Duncan C; Jacobsohn DA; Bollard CM; Cruz CRY; Malatpure A; Farag SS; Renbarger J; Liu H; Bakoyannis G; Hanash S; Paczesny S
Blood; 2020 Apr; 135(17):1428-1437. PubMed ID: 31972009
[TBL] [Abstract][Full Text] [Related]
14. Donor-Recipient Matching for KIR Genotypes Reduces Chronic GVHD and Missing Inhibitory KIR Ligands Protect against Relapse after Myeloablative, HLA Matched Hematopoietic Cell Transplantation.
Faridi RM; Kemp TJ; Dharmani-Khan P; Lewis V; Tripathi G; Rajalingam R; Daly A; Berka N; Storek J; Masood Khan F
PLoS One; 2016; 11(6):e0158242. PubMed ID: 27341514
[TBL] [Abstract][Full Text] [Related]
15. Heterogeneity of chronic graft-versus-host disease biomarkers: association with CXCL10 and CXCR3+ NK cells.
Kariminia A; Holtan SG; Ivison S; Rozmus J; Hebert MJ; Martin PJ; Lee SJ; Wolff D; Subrt P; Abdossamadi S; Sung S; Storek J; Levings M; Aljurf M; Arora M; Cutler C; Gallagher G; Kuruvilla J; Lipton J; Nevill TJ; Newell LF; Panzarella T; Pidala J; Popradi G; Szwajcer D; Tay J; Toze CL; Walker I; Couban S; Storer BE; Schultz KR
Blood; 2016 Jun; 127(24):3082-91. PubMed ID: 27020088
[TBL] [Abstract][Full Text] [Related]
16. Validated graft-specific biomarkers identify patients at risk for chronic graft-versus-host disease and death.
Logan BR; Fu D; Howard A; Fei M; Kou J; Little MR; Adom D; Mohamed FA; Blazar BR; Gafken PR; Paczesny S
J Clin Invest; 2023 Aug; 133(15):. PubMed ID: 37526081
[TBL] [Abstract][Full Text] [Related]
17. Use of the NIH consensus criteria in cellular and soluble biomarker research in chronic graft-versus-host disease: A systematic review.
Milosevic E; Babic A; Iovino L; Markovic M; Grce M; Greinix H
Front Immunol; 2022; 13():1033263. PubMed ID: 36389657
[TBL] [Abstract][Full Text] [Related]
18. Prognostic factors of chronic graft-versus-host disease after allogeneic blood stem-cell transplantation.
Pavletic SZ; Smith LM; Bishop MR; Lynch JC; Tarantolo SR; Vose JM; Bierman PJ; Hadi A; Armitage JO; Kessinger A
Am J Hematol; 2005 Apr; 78(4):265-74. PubMed ID: 15795914
[TBL] [Abstract][Full Text] [Related]
19. Composite biomarker panel for prediction of severity and diagnosis of acute GVHD with T-cell-depleted allogeneic stem cell transplants-single centre pilot study.
Min SS; Mehra V; Clay J; Cross GF; Douiri A; Dew T; Basu TN; Potter V; Ceesay MM; Pagliuca A; Sherwood RA; Vincent RP
J Clin Pathol; 2017 Oct; 70(10):886-890. PubMed ID: 28450387
[TBL] [Abstract][Full Text] [Related]
20. A diagnostic classifier for pediatric chronic graft-versus-host disease: results of the ABLE/PBMTC 1202 study.
Cuvelier GDE; Ng B; Abdossamadi S; Nemecek ER; Melton A; Kitko CL; Lewis VA; Schechter T; Jacobsohn DA; Harris AC; Pulsipher MA; Bittencourt H; Choi SW; Caywood EH; Kasow KA; Bhatia M; Oshrine BR; Chaudhury S; Coulter D; Chewning JH; Joyce M; Savaşan S; Pawlowska AB; Megason GC; Mitchell D; Cheerva AC; Lawitschka A; Ostroumov E; Schultz KR
Blood Adv; 2023 Jul; 7(14):3612-3623. PubMed ID: 36219586
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
